Journal
BASIC RESEARCH IN CARDIOLOGY
Volume 116, Issue 1, Pages -Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00395-021-00854-y
Keywords
lncRNA; Cardiac fibrosis; SAFB; RNA-seq; RNA pol II
Categories
Funding
- National Natural Science Foundation of China [81872871, 82070283, 81530010, 82073844]
Ask authors/readers for more resources
SAIL is a novel anti-fibrotic lncRNA that regulates cardiac fibrosis by interfering with the transcription of fibrosis-related genes mediated by SAFB. Both SAIL and SAFB have the potential to become new therapeutic targets for cardiac fibrosis.
Long non-coding RNAs (lncRNAs) account for a large proportion of genomic transcripts and are critical regulators in various cardiac diseases. Though lncRNAs have been reported to participate in the process of diverse cardiac diseases, the contribution of lncRNAs in cardiac fibrosis remains to be fully elucidated. Here, we identified a novel anti-fibrotic lncRNA, SAIL (scaffold attachment factor B interacting lncRNA). SAIL was reduced in cardiac fibrotic tissue and activated cardiac fibroblasts. Gain- and loss-of-function studies showed that knockdown of SAIL promoted proliferation and collagen production of cardiac fibroblasts with or without TGF-beta 1 (transforming growth factor beta1) treatment, while overexpression of SAIL did the opposite. In mouse cardiac fibrosis induced by myocardial infarction, knockdown of SAIL exacerbated, whereas overexpression of SAIL alleviated cardiac fibrosis. Mechanically, SAIL inhibited the fibrotic process by directly binding with SAFB via 23 conserved nucleotide sequences, which in turn blocked the access of SAFB to RNA pol II (RNA polymerase II) and reduced the transcription of fibrosis-related genes. Intriguingly, the human conserved fragment of SAIL (hSAIL) significantly suppressed the proliferation and collagen production of human cardiac fibroblasts. Our findings demonstrate that SAIL regulates cardiac fibrosis by regulating SAFB-mediated transcription of fibrotic related genes. Both SAIL and SAFB hold the potential to become novel therapeutic targets for cardiac fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available